Under the new CEO, Kotak said it would monitor the progress of Gland Pharma’s proposed B2C strategy in regulated markets, especially given the CEO’s limited experience in these pharma markets, which contribute 75% of Gland’s total sales. Additionally, Kotak will watch for traction in Rest of World (RoW) markets.
